Thus, the burning question undergirding the arc of this article is regarding the mechanisms that yoke centrosome clustering pathways to centrosome amplification pathways in AR-low TNBC, which is a breast cancer subgroup notorious for its rampant centrosome amplification and aggressive disease course. Here, AR is linked to breast cancer.